Combigene

April – June 2022
• Net sales: 4,738 (0) TSEK.
• Other operating revenues: 9,865 (839) TSEK.
• Profit from financial items: 4,516 (-15,402) TSEK.
• Earnings per share: 0.23 (-0.85) SEK.

January – June 2022
• Net sales: 16,141 (0) TSEK.
• Other operating revenues: 12,967 (5,957) TSEK.
• Profit from financial items: 1,832 (-26,258) TSEK.
• Earnings per share: 0.09 (-1.78) SEK.
• Liquidity as per the end of the reporting period: 125,953 (82,376) TSEK.
• Equity ratio as per the end of the reporting period: 97 (97)%.

Events during the period
• CombiGene strengthens its project management capabilities with Alvar Grönberg as Senior Project Manager
• On May 19, 2022, CombiGene AB held its Annual General Meeting (AGM) in Stockholm.
– The AGM resolved, in accordance with the nomination committee’s proposal, on reelection of Peter Nilsson, Bert Junno, Jonas Ekblom, Per Lundin and Gunilla Lundmark as board members. Bert Junno was re-elected as the chairman of the board of directors. The AGM re-elected the audit firm Mazars AB as auditor.
– The AGM resolved, in accordance with the board of directors’ proposal, on the implementation of LTI 2022, directed issue of 900,000 warrants, transfer of the warrants to participants in LTI 2022 and transfer of warrants to cover costs for LTI 2022 and authorisation to enter into swap agreement. A more detailed description of LTI 2022 can be found in the notice convening the Annual General Meeting 2022.
• CombiGene participates in GeneNova collaboration to develop AVV-based gene therapies.

Events after the end of the period
• There have been no significant events after the end of the period.

Link to the report